TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Argenica Therapeutics Ltd ( (AU:AGN) ) just unveiled an update.
Argenica Therapeutics Limited announced the successful passage of all resolutions at its Annual General Meeting held on November 12, 2025. The approval of resolutions, including the adoption of the remuneration report, re-election of a director, and approval of a 10% placement capacity, reflects strong shareholder support and positions the company for continued strategic growth.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a company operating in the biotechnology industry, focusing on the development of therapeutic products. The company is listed on the Australian Securities Exchange under the ticker AGN and is based in Perth, Australia.
Average Trading Volume: 586,727
Technical Sentiment Signal: Sell
Find detailed analytics on AGN stock on TipRanks’ Stock Analysis page.